KAT6A

Overview

KAT6A (lysine acetyltransferase 6A, formerly MYST3 or MOZ) encodes a MYST-family histone acetyltransferase involved in chromatin regulation and transcriptional control. In esophageal adenocarcinoma (EAC), KAT6A is recurrently mutated and has been nominated as a statistically significant candidate driver gene in a large WGS/WES study, though functional validation in EAC is pending.

Alterations observed in the corpus

• Mutated in 7/145 (5%) of esophageal adenocarcinomas (EAC) in a WGS/WES cohort; lysine acetyltransferase (formerly MYST3) nominated as significant driver candidate, not experimentally validated in this study PMID:23525077
• Novel amplification target gene in lung ADC identified in the TCGA pan-lung cancer cohort PMID:27158780

Cancer types (linked)

• EAC (Esophageal Adenocarcinoma): mutated in 5% (7/145 tumors); statistically significant candidate driver in WGS/WES discovery analysis PMID:23525077

Co-occurrence and mutual exclusivity

• Co-nominated alongside ELMO1, DOCK2, SPART, TLR4, AKAP6, HECW1, AJAP1, and NUAK1 as additional statistically significant candidates in EAC PMID:23525077

Therapeutic relevance

• No approved targeted agents in EAC; KAT6A acetyltransferase activity may represent a targetable epigenetic vulnerability PMID:23525077

Open questions

• Functional validation of KAT6A as a driver in EAC is lacking; the study nominates it statistically but provides no experimental confirmation PMID:23525077

Sources

• PMID:23525077

This page was processed by crosslinker on 2026-05-09. - PMID:27158780

This page was processed by wiki-cli on 2026-05-14.